Tonix Pharmaceuticals Files 8-K

TL;DR

TNXP filed an 8-K, updating corporate info and office locations.

AI Summary

Tonix Pharmaceuticals Holding Corp. filed an 8-K on September 17, 2025, reporting on other events and financial statements. The filing indicates the company's principal executive offices are located at 26 Main Street, Suite 101, Chatham, New Jersey, 07928, with a business phone number of (862) 904-8182. The company was formerly known as Tamandare Explorations Inc. before a name change on March 20, 2008.

Why It Matters

This 8-K filing provides updated corporate information and signals ongoing regulatory compliance for Tonix Pharmaceuticals.

Risk Assessment

Risk Level: low — This filing is a routine corporate update and does not contain material financial or operational news.

Key Players & Entities

• Tonix Pharmaceuticals Holding Corp. (company) — Registrant
• September 17, 2025 (date) — Report Date
• 26 Main Street, Suite 101, Chatham, New Jersey, 07928 (location) — Principal Executive Offices
• (862) 904-8182 (phone_number) — Business Phone
• Tamandare Explorations Inc. (company) — Former Company Name
• March 20, 2008 (date) — Date of Name Change

FAQ

Filing Documents

• tnxp-8k_091725.htm (8-K) — 28KB
• ex99-01.htm (EX-99.01) — 34KB
• tnxp_001.jpg (GRAPHIC) — 3KB
• 0001999371-25-013413.txt ( ) — 241KB
• tnxp-20250917.xsd (EX-101.SCH) — 3KB
• tnxp-20250917_lab.xml (EX-101.LAB) — 33KB
• tnxp-20250917_pre.xml (EX-101.PRE) — 22KB
• tnxp-8k_091725_htm.xml (XML) — 3KB

01

Item 7.01 Regulation FD Disclosure. On September 17, 2025, Tonix Pharmaceuticals Holding Corp. (the "Company") announced the in-licensing of worldwide rights to its TNX-4800 (formerly known as mAb 2217LS) product candidate. A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01

Item 8.01. Other Events. On September 17, 2025, the Company announced the in-licensing of worldwide rights to TNX-4800, a long-acting human monoclonal antibody that targets the outer surface protein A ("OspA") of Borrelia burgdorferi, the causative agent of Lyme disease in humans. TNX-4800 was developed by researchers at UMass Chan Medical School. TNX-4800 is a fully human monoclonal antibody with an engineered extended half-life that targets the OspA on Lyme-causing Borrelia bacteria. By binding OspA, TNX-4800 blocks the maturation of Borrelia burgdorferi in the mid-gut of infected deer ticks. The mAb 2217LS was derived from mAb 2217 by amino acid substitutions that crystallizable fragment domain to prolong the serum half-life. A single subcutaneous springtime administration is designed to maintain protective antibody titers through the Fall, or the entire U.S. tick season, providing pre-exposure prophylaxis against Lyme disease without relying on the recipient's immune system to generate antibodies. By delivering a well-characterized antibody directly, TNX-4800 has been shown to block transmission of the major Borrelia genospecies from ticks to animals. TNX-4800 sidesteps the multidose schedules required for OspA vaccines in development and FDA-approved vaccines that have been withdrawn from the market due to concerns about increased risk of autoimmunity. The Company intends to advance TNX-4800 through additional clinical trials with the goal of submitting a Biologics Licensing Application to the U.S. Food and Drug and Administration.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibit No. Description. 99.01 Press Release of the Company, September 17, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TONIX PHARMACEUTICALS HOLDING CORP. Date: September 17, 2025 By: /s/ Bradley Saenger Bradley Saenger Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR